Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00458393 · ClinicalTrials.gov registry record · Phase 3
Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 2,499
- Enrollment target
NCT00458393 is a Phase 3 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 2,499 participants.
The verdict
NCT00458393, a Phase 3 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,499 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether daily use of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) can prevent HIV infection in men who also receive HIV counseling, condoms, and treatment for other sexually transmitted infections (STIs).
Interventions
- DRUG Placebo
- DRUG daily TDF/FTC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,499 participants |
| Start Date | 2007-06 |
| Est. Completion | 2014-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00458393
The ClinicalTrials.gov registry entry for NCT00458393 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,499 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00458393 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00458393 about?
NCT00458393 is a clinical study titled "Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men". The purpose of this study is to determine whether daily use of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) can prevent HIV infection in men who also receive HIV counseling, condoms, and treatment for other sexually transmitted infections (STIs).
What is the current status of trial NCT00458393?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,499 participants. The study started on 2007-06. Estimated completion is 2014-02.
What interventions are being tested in trial NCT00458393?
The interventions under investigation include: Placebo (DRUG), daily TDF/FTC (DRUG).
Who is sponsoring clinical trial NCT00458393?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.